Quotient Research has announced that it is supporting a key industry trend with comprehensive biomarker services for drug development.
The company said it offers expertise in marker development, the establishment and validation of methods, and routine quantification of almost 250 different biomarkers.
Biomarkers can be correlated with biological events to validate drug targets or to predict drug response.
In addition, they may be used to characterise and stratify patient populations, helping researchers understand the extent to which a new drug reaches its intended therapeutic target.
Importantly, data from clinically validated biomarkers is becoming increasingly required by regulators as they make decisions regarding drug approval.
